Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Children's Oncology Group
AbbVie
Children's Oncology Group
National Cancer Institute (NCI)
Case Comprehensive Cancer Center
Canadian Cancer Trials Group
Children's Oncology Group
Children's Oncology Group
M.D. Anderson Cancer Center
NYU Langone Health